Usher Syndrome |
Deafness-retinitis pigmentosa syndrome; dystrophia retinae pigmentosa-dysostosis syndrome; Graefe-Usher syndrome; Hallgren syndrome; Retinitis pigmentosa-deafness syndrome |
Clinical Trial: Study of Dietary N-3 Fatty Acids in Patients with Retinitis Pigmentosa and Usher Syndrome
This study has been terminated.
|
Purpose
OBJECTIVES: I. Examine the concentration of docosahexanoic acid (DHA) and other n-3 fatty acids in plasma, erythrocyte, and adipose tissue in patients with various forms of retinitis pigmentosa and Usher syndrome. II. Determine the synthesis and catabolism of DHA from linolenic acid in these patients. III. Determine the synthesis, absorption, and catabolism of DHA under different dietary conditions in these patients.
| Condition |
|---|
| Usher Syndrome Retinitis Pigmentosa |
MedlinePlus related topics: Eye Diseases; Genetic Disorders; Hearing Disorders and Deafness; Retinal Disorders
Study Type: Observational
Study Design: Screening
Expected Total Enrollment: 100
Study start: October 1999
PROTOCOL OUTLINE: Patients may participate in one or more of the arms of this study. Arm I (adipose tissue study): Adipose tissue is collected from the buttocks of patients with Usher II retinitis pigmentosa (RP), patients with non-Usher RP, and control subjects. Dietary histories are obtained from all patients and subjects. Arm II (isotope study): Patients meeting the same criteria as in arm I receive oral D5-labeled linolenic acid and oral D4-labeled linolenic acid that is dissolved in oil and incorporated into foods. Subjects must avoid eating fish and shellfish during the 35 days of the isotope study. Blood samples are collected at 0, 8, 24, and 48 hours, daily on days 3-7, and then on days 10, 18, and 35. Arm III (flaxseed oil feeding): Patients with all types of RP and control subjects receive flaxseed oil, a form of linolenic acid, for 12 weeks. Subjects may also receive high oleic safflower oil or olive oil as a control fat for 12 weeks. Subjects complete a diet history at the end of each fatty acid supplementation period. All subjects must follow a diet free of seafood and fish oil supplements.
Eligibility
Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
PROTOCOL ENTRY CRITERIA:
- Retinitis pigmentosa, including: Usher syndrome (types I and II) Simplex
- The following inheritance patterns eligible: X-linked recessive; Autosomal dominant; Autosomal recessive
Location Information
Oregon
Oregon Health Sciences University, Portland, Oregon, 97201-3098, United States
William Connor, Study Chair, Oregon Health and Science University
More Information
Record last reviewed: July 2002
Last Updated: October 13, 2004
Record first received: October 18, 1999
ClinicalTrials.gov Identifier: NCT00004345
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


